Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: GlobeNewswire
France, March 16, 2019 (GLOBE NEWSWIRE) -- Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attackPraluent is the only EU-approved PCSK9 inhibitor with cardiovascular outcomes data that showed an association with reduced death from any cause PARIS and TARRYTOWN, NY - March 15, 2019 - The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors. "Many patients with atherosclerotic cardiovascular disease often struggle to control their high LDL-cholesterol levels, despite lifestyle modifications and treatment with
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi to overhaul US operations of vaccines, cut jobs [Reuters]Reuters
- Sanofi to overhaul US operations of vaccines, cut jobs [Yahoo! Finance]Yahoo! Finance
- Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1) [Yahoo! Finance]Yahoo! Finance
- Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)PR Web
- COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- 3/20/24 - Form 6-K
- SNY's page on the SEC website